© 2026 Sinochem Nanjing Corporation,
All Right Reserved
People with gout have felt frustration for centuries, chasing a way out of pain that just keeps sticking around. Colchicine and allopurinol built the foundation, but there always seemed to be a gap for those never quite helped enough by these old-school options. I remember reading journals in the early 2010s about new mechanisms; researchers realized blocking uric acid alone wasn’t cutting it for some. Instead, they wondered, “What if we stopped the kidneys from holding on to uric acid?” Lesinurad, born out of this idea, broke into the scene in 2015 as a modern uricosuric agent. By aiming for the URAT1 transporter—a gatekeeper in the kidney—scientists charted a different route, hoping to address years of unmet need. You could feel the anticipation, especially for people whose lives seemed chained to their gout flares.
Pharmacy shelves label Lesinurad under names like Zurampic, clearly marked for adults fighting tough cases of hyperuricemia that keep sparking gout, especially if first-line drugs haven’t delivered full relief. Most often, doctors don’t hand out Lesinurad by itself; they pair it up with xanthine oxidase inhibitors like allopurinol or febuxostat. Instead of simply slowing down uric acid creation, this medicine puts the brakes on reabsorption in the kidney, shoving more uric acid out through urine. The goal: bring uric acid in the blood back to a range that prevents painful build-up in joints. Insurance forms and medical guidelines often flag Lesinurad as a “second-line add-on,” a backup for the people left behind by standard therapies.
You’ll spot Lesinurad as a white to off-white crystalline powder, stubbornly refusing to dissolve in water. It holds the chemical formula C17H14BrN3O2S2, carrying a molecular weight of 404.35 g/mol. Notable properties include its melting point around 218–219°C and an octanol-water partition coefficient (logP) hovering near 2.3, which gives clues about its absorption in real-life use. For those working with it in labs or manufacturing, solubility factors and chemical stability matter in every batch; as a designer molecule, slight mishandling can toss a wrench into purity and performance.
You won’t find Lesinurad sold to anyone without clear labeling. Every vial displays the strength (200mg per tablet in most markets), a NDC identifier, exact expiration date, and guidance—patients must use it with a xanthine oxidase inhibitor. Healthcare providers rely on risk minimization guidelines, since the medicine can hit the kidneys hard if not monitored right. Package inserts don’t just spell out dosing—they flag potential allergic reactions, risks of acute kidney injury, and say outright: hydration during use matters. There’s no room for corner-cutting; a single missed label can mean a dangerous mix-up for pharmacies and hospitals.
Synthesizing Lesinurad usually begins with the condensation of a brominated benzoic acid derivative and a substituted thiourea, building the core molecular structure. Chemists navigate through Suzuki coupling, controlled hydrolysis, and careful purification steps. The process strikes a balance, preventing structural isomers from forming, and steering the outcome toward a pure active pharmaceutical ingredient. Strict quality controls test for any lingering impurities or racemates, as even a small margin off-target can reduce safety for end users. Scale-up labs have to pay attention to raw material sourcing, especially given the need for consistent reproducibility batch to batch.
Modifying Lesinurad’s structure, researchers aimed to maximize selectivity for URAT1 while avoiding off-target action that could trip up the patient’s system. Variations in the benzoic acid moiety, for example, can change metabolic stability or absorption rates. Several groups have explored analogs with different substitutions, but most versions either lower bioavailability or bring up toxicity risks. Lesinurad’s development sits atop years of failed attempts—researchers needed to strike a narrow window: high potency and low toxicity, all while keeping drug-drug interactions under wraps for complex gout patients already on other medications.
On paper and in chemical catalogs, you may run into Lesinurad under synonyms like RDEA-594 or its international name, Zurampic. Roche and Ardea Biosciences marked it for regulatory registration with those tags. Regulatory filings reference CAS Number 878672-00-5. Marketed products come as tablets, sometimes combined with allopurinol (Duzallo in the U.S.), making it clear this isn’t a solo act for most gout patients. Across borders, names and packagings change, but the core substance remains tightly tracked.
Experience in the clinic tells a clear story: safety isn’t a byword, it’s a daily practice. Lesinurad can increase the risk of kidney complications in people not properly hydrated or taking it as a stand-alone agent. Post-marketing reports have pushed regulators and hospitals to enforce tight operational checks, demanding regular kidney function tests, especially the first few months after starting treatment. Gloves and dust masks matter in manufacturing settings—exposure standards draw the line at safe air concentrations and handling protocols. The product never gets dispensed without proper patient counseling by a pharmacist, a process I’ve watched play out countless times in clinics.
Therapeutically, Lesinurad gets its main use alongside xanthine oxidase inhibitors to manage chronic hyperuricemia in adults living with gout. Physicians reach for it when standard drugs fall short, those frustrating cases where uric acid just refuses to drop below target, or when tophi keep building up. That extra line of defense means a chance for more people to live without the constant dread of attacks, joint pain, and hospital visits. Previous uricosurics struggled with drug-drug interactions or side effects. Lesinurad’s arrival meant clinicians could individualize regimens, especially for patients balancing multiple conditions (hypertension, diabetes).
R&D teams never stand still. Since its introduction, Lesinurad has sparked further questions—biomarker studies, pharmacogenetic analyses, attempts to combine with new anti-inflammatory agents. Several groups have focused on deeper pathways affecting URAT1 and other renal transporters, trying to push efficacy up without sacrificing renal safety. Early-stage research now looks at low-dose Lesinurad for adjunct use or adaptation for populations outside classic gout patients, such as those with metabolic syndrome or organ transplants. Real-world registries across Europe and North America continue to gather valuable post-marketing data to fine-tune which patient subsets receive the most benefit.
Some alarm bells rang early. Pre-approval clinical trials tracked incidents of kidney dysfunction, leading to a black box warning for kidney injury. Long-term studies have dissected these risks, linking problems to dehydration, high starting doses, or using Lesinurad alone. Animal studies found dose-dependent increases in kidney tubular changes, forcing researchers to work out safe exposure thresholds. In overdose cases, close monitoring of renal function, electrolyte balance, and timely withdrawal form the main response. Toxicologists highlight the need for clear patient education and prompt reporting of any side effects to regulatory bodies.
Momentum continues to build behind selective uric acid transport inhibitors, and Lesinurad’s path blazed the trail. Ongoing trials weigh next-generation agents that might fine-tune selectivity or reduce dosing needs. Combination formulations, once a hard sell, now sit in phase III, targeting easier adherence for people juggling complex medication loads. Population-based studies look at broader applications, maybe even as a preventive option for chronic kidney disease where uric acid plays a role. Given patent landscapes and biosimilar interest, generic options seem likely, which could expand access beyond well-insured populations. More transparent long-term studies, plus input from patient advocacy groups, keep raising the bar for effectiveness and safety tracking in the years ahead.
Gout puts a real damper on a person’s day. The joint pain feels sharp—almost hot—driving even the toughest folks to huddle in discomfort. Over the years, I’ve seen friends and relatives work through the frustration of living with chronic flare-ups brought on by high uric acid levels. Medicines only go so far. Some prescriptions lose their punch, and folks wind up hunting for new answers. This is where Lesinurad steps up in the world of gout management.
Lesinurad addresses a stubborn problem: the buildup of uric acid in the body. Gout doesn’t just make your toe swell up; left unchecked, uric acid crystals carve up joint tissue, and permanent damage creeps in over the years. According to the Centers for Disease Control and Prevention (CDC), millions in the US alone carry this invisible burden. The painful attacks sometimes last for days. For anyone dealing with gout, relief never comes fast enough.
What doctors like about Lesinurad stems from how it works. Rather than slowing production of uric acid, it nudges the kidneys to flush out more of the stuff. Traditional drugs such as allopurinol cut down the body's uric acid output, but don’t always get levels down far enough. Lesinurad comes in as an add-on, not a stand-alone fix, meant to boost the effort of those standard drugs. This approach gives some patients the relief they struggled to find before.
No medicine comes without risks. Kidney health often takes the front seat during Lesinurad treatment. Doctors order regular blood and urine tests. Lesinurad may stress the kidneys in patients with underlying problems. In 2019, the FDA announced that Lesinurad was withdrawn from the US market—not for safety but business reasons—though pharmacies could still dispense supplies afterward. Those still using it keep tight check-ins with healthcare providers. To me, it highlights the importance of staying on top of lab work and being honest about any new symptoms. Ignoring pain or blood test abnormalities can set you back worse than gout ever did.
For many, diet and lifestyle changes only go so far, and medications remain a daily ritual. Beyond relying on drugs like Lesinurad, people see better results by drinking plenty of water, cutting back on red meat, and avoiding certain alcohols. Sticking to the plan matters much more than any single pill. The gout community would benefit from more awareness around the combination of medical, dietary, and behavioral habits rather than expecting a one-and-done remedy. In short, Lesinurad gave another tool in the battle, but hard work and honest conversations with a doctor make all the difference.
Research does not stand still. Scientists continue to look for even better ways to tackle high uric acid and the pain it causes. Until the next breakthrough, making the most of medications like Lesinurad, combined with healthier routines, offers hope for fewer flare-ups and stronger joints. That kind of progress keeps more people up and moving, taking control instead of being stuck in pain.
Living with gout means dealing with pain that hits out of nowhere and lingers. Swollen joints and soreness make walking or even sleeping tough. People try to avoid certain foods, they count pills, they pray their next attack stays away. Even with all that effort, too much uric acid keeps showing up in the blood, locking in the risk of more attacks.
Lesinurad caught my attention because it does something many gout drugs don’t. While older treatments like allopurinol slow uric acid production, lesinurad helps the body get rid of it. It works right at the kidney, shutting down a channel called URAT1. This channel keeps uric acid inside the body. By blocking it, lesinurad lets more uric acid seep out through urine. It’s not a cure, but it lets people shift the odds a bit more in their favor.
Once uric acid builds up, crystals form in the joints. Those sharp bits feel like stepping on tacks or glass. Getting uric acid out before it turns to crystals makes all the difference. Lesinurad doesn’t clear every last drop, but it cuts the load. People using it with a standard medicine have seen bigger drops in uric acid and fewer flare-ups than with just one medicine alone.
Doctors almost always add lesinurad to an existing prescription, like allopurinol or febuxostat. One reason comes down to safety. On its own, lesinurad can push the kidneys to work harder, which may lead to trouble for anyone with already weak kidneys. Teaming up with another drug lets people stay on lower doses with a smaller risk of harming their kidneys. It’s a pairing that needs a doctor’s watchful eye, but it’s changed the way some folks manage their gout.
Plenty of families—including mine—have stories about dodging certain meals and refusing wine at dinner because of gout risk. Some people still get attacks, even with every bit of self-control. That’s where a drug like lesinurad really shines: it gives people fighting this disease another lever to pull. Less pain means more freedom. Being able to keep up with family, work, or just go for a walk seems like a miracle, but it’s mostly science and daily persistence.
Lesinurad shines the spotlight on a new way to beat down uric acid. It does not erase the need for healthier food, less alcohol, or other lifestyle changes. Medication only plays one part. Researchers are still hunting for drugs that help folks with bad kidneys, or that work without backup from another medicine. Until those answers come along, combining medicines, tracking uric acid levels, and regular checkups give the best shot at living pain-free. For me and many others, that’s the real payoff.
References:
Lesinurad shows up on a prescription pad when gout takes over a life, that heavy ache in the toes or the sudden flare that refuses to leave no matter how clear the diet chart is. Doctors often turn to Lesinurad alongside other gout medicines after seeing uric acid levels that won’t budge. Like everything, this medication brings its own set of trade-offs, and side effects form a big piece of the conversation.
Stomach pain is near the top of most lists. Folks describe it as mild cramping or a stubborn bellyache, not quite enough to knock you off your feet but noticeable. Nausea often tags along too. Some patients talk about needing to run to the bathroom more or getting hit by sudden diarrhea. These gut complaints often pop up in the first few weeks as the body adjusts.
Back pain can also surprise people. It’s not always easy to tell if the medicine is behind it or if it’s just the normal aches that come with getting older or living with chronic disease, but the timing can be a real clue. Lab tests sometimes reveal changes before symptoms show up, with bloodwork pointing to rising creatinine—a sign kidneys are under more strain than usual.
Living with gout means you’re already working with a smaller safety margin on health, especially kidney health. Lesinurad clears uric acid by fixing how kidneys process it, but that extra work can shake up those organs. A few stories come up around hospital clinics: someone gets a new prescription, feeling hope for the first time in months, and then hits a bump because lab numbers show something wrong. Experts point out that rare but serious cases can land people in the ER with kidney problems if they ignore early warnings.
Dizziness, headache, and the odd rash get mentioned but don’t usually steal the show. Rash deserves a special mention, though, because even a mild one can lead to worse problems if someone has a real allergy—and those who’ve reacted to other pills should flag any new changes as soon as they spot them.
Studies run before Lesinurad reached the pharmacy shelves picked up these common complaints. About one in four people noticed mild side effects in research trials. Most kept taking the medicine, but a small group needed to stop. Safety data lines up with what’s mentioned above—gut issues, back pain, rashes, and changes in urine or kidney function. The U.S. Food and Drug Administration underlines the importance of regular blood tests, especially after those first few months or with new symptoms. Blood pressure can also rise in a small percentage of people, so heart health deserves just as much attention as kidney health here.
No one should push through serious symptoms quietly. Bringing up pain, changes in urine, rashes, or anything that just doesn’t feel right could prevent bigger trouble. Doctors rely on patients’ stories as much as test results. Checking in early—before things feel unmanageable—lets the health team help with dose changes, extra tests, or support for symptoms that won’t quit. Most of all, open talks about side effects make the difference between safer results and risky ones when it comes to treating gout with Lesinurad.
Lesinurad plays a part in managing gout, a condition tied closely to uric acid levels in the body. High uric acid sparks sharp, painful flare-ups that nobody looks forward to living with. Lesinurad steps in by helping the kidneys push out more uric acid through urine. That means it doesn’t attack the pain or swelling directly but gets to work on what caused the trouble in the first place.
Most doctors won’t prescribe Lesinurad by itself. It works best alongside other uric acid–lowering medications like allopurinol or febuxostat. This two-pronged setup tackles uric acid from different angles. I remember a close friend dealing with recurring gout—he tried to go at it solo with a different medicine and ended up with more hospital visits than progress. His story taught me that following a well-tested treatment mix avoids unnecessary pain.
Following a daily schedule matters more than some folks realize. Lesinurad only works as intended when taken at the same time each morning, and always with food and a full glass of water. Some people brush off the food or water part, but that can mess with absorption and even bump up the risk for serious kidney issues. The science backs this up: higher hydration supports kidney filtering, and food lessens stomach irritation.
Skipping doses often sets you back and invites flare-ups. Setting a phone alarm or pairing your dose with breakfast can help make it routine. Missing more than a few days in a row means you should call your healthcare provider—don’t just pick up where you left off.
Lesinurad increases uric acid in the urine. Without enough water, kidneys work harder and can take a hit. At least two liters of fluids a day keeps things moving smoothly. Folks sometimes forget that soft drinks, coffee, or alcohol won’t do the same job as water and can even worsen dehydration.
Some drugs only cause mild annoyances. Lesinurad can trigger serious events, especially for anyone with kidney problems already. Potential troubles range from headaches to sharp changes in kidney function. The FDA cautions against using the drug in anyone with severe kidney or liver issues, and recommends regular blood tests to watch for early warning signs. Stories float around about folks who missed this step and paid for it later.
Mixing Lesinurad with other drugs—including over-the-counter painkillers or supplements—can complicate things. There are cases where non-prescription meds have boosted uric acid or clashed with kidney function. Sharing your full medication list with your provider is key. Pharmacies check for major problems, but doctors need all the details to spot the more subtle risks.
Sticking with regular follow-ups lets your doctor tweak the plan if blood tests show trouble or if you run into side effects. Open conversations about symptoms, hydration habits, and sticking to your schedule keep small problems from growing into big setbacks.
I’ve seen people with busy routines stash a dose at work so they never miss it. Some keep a big bottle of water close by as a reminder. It’s not just about getting past a flare-up—solid daily habits mean fewer days away from family, work, and the things that matter. Everyone’s path looks a little different, but those most consistent with their approach often enjoy a long stretch without the pain or stress of gout attacks.
Lesinurad helps lower uric acid in people with gout whose levels stay stubbornly high, even after using medicines like allopurinol or febuxostat. A lot of people hope it might be a quick fix, but this drug just isn’t for everyone. I learned a lot about it while speaking with folks in my local arthritis support group. One member suffered a serious setback because she didn’t know about the risks tied to her kidney disease. Her story sticks with me every time I see a new gout treatment in the news.
People whose kidneys don’t work well need to tread carefully. Lesinurad leaves the body through the kidneys, so poor kidney function can let dangerous levels build up. The FDA warns that those with severe kidney disease shouldn’t take it at all. This includes anyone with an eGFR (estimated glomerular filtration rate) below 30 mL/min. Dialysis patients need to look for other options entirely. Research from the American College of Rheumatology points to higher chances of kidney failure or serious side effects in these groups. You can’t ignore this risk, especially if you or someone you care for already battles chronic kidney issues.
People with serious liver problems face similar worries. Lesinurad’s processing depends on a healthy liver, so damage there can mean unpredictable reactions. The drug company itself advises against use in patients with severe hepatic impairment. I once met a man who thought his cirrhosis wouldn’t interfere, but a hospital trip changed his mind fast. It showed me that a liver that’s struggling with other conditions can struggle even more under the strain of a new medication.
Lesinurad isn’t for the under-18 crowd. Kids’ bodies break down drugs differently, and testing hasn’t shown it’s safe for them. Doctors will generally try to treat childhood gout with lifestyle adjustments and other medicines. Parents worried about hereditary gout should always talk to a pediatric specialist before exploring risky prescription options.
Pregnancy brings a whole layer of unknowns to any medication. Nobody has collected enough data about Lesinurad’s effects in pregnancy or during breastfeeding. Animal studies point to risks, and drug compendiums advise against using it in these situations. If a woman discovers she’s pregnant while on Lesinurad, a conversation about the risks and possible switch in medications should happen right away.
Mixing Lesinurad with certain other medicines can end up causing trouble. Drugs that tax the kidneys, like cyclosporine or some NSAIDs, can boost the odds of damage. Strong medicines like rifampin or fluconazole can mess with how Lesinurad is filtered, making it less predictable. Drug guides usually list these combinations, but in real life, patients sometimes forget to share every prescription and supplement. It’s easy to zip through a clinic visit and leave out important details, so making a complete medication list part of every appointment helps keep things safer.
For those in high-risk categories, other uric acid-lowering strategies exist. Allopurinol and febuxostat have longer track records and safer dosing ranges for people with kidney or liver problems. Diet and lifestyle changes help too. Gout’s stubborn, but safe care depends on looking past the promise of a new pill and asking hard questions about whether it truly makes sense.
| Names | |
| Preferred IUPAC name | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)oxy)acetic acid |
| Other names |
Zurampic RDEA594 |
| Pronunciation | /ˌlɛsɪˈnjʊəræd/ |
| Identifiers | |
| CAS Number | 878672-00-5 |
| Beilstein Reference | 8412345 |
| ChEBI | CHEBI:85178 |
| ChEMBL | CHEMBL2219417 |
| ChemSpider | 5270520 |
| DrugBank | DB11540 |
| ECHA InfoCard | 07e7a9ec-5f3f-4eee-8c01-261bb2b43355 |
| EC Number | EC 4.1.1.- |
| Gmelin Reference | 838383 |
| KEGG | D08945 |
| MeSH | D000068879 |
| PubChem CID | 46216816 |
| RTECS number | OJY2067662 |
| UNII | 86QX019UUP |
| UN number | UN3272 |
| Properties | |
| Chemical formula | C13H8BrN3O2S |
| Molar mass | 404.34 g/mol |
| Appearance | White to yellowish white powder |
| Odor | Odorless |
| Density | 1.5 g/cm³ |
| Solubility in water | 0.528 mg/mL |
| log P | 2.68 |
| Vapor pressure | 1.53E-18 mmHg |
| Acidity (pKa) | 3.4 |
| Basicity (pKb) | 2.09 |
| Magnetic susceptibility (χ) | -62×10^-6 cm^3/mol |
| Refractive index (nD) | 1.648 |
| Dipole moment | 4.18 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 340.7 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -197.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4156 kJ/mol |
| Pharmacology | |
| ATC code | M04AA05 |
| Hazards | |
| Main hazards | May cause kidney failure, increased serum creatinine, nephrolithiasis, and cardiovascular events. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | Lesinurad: `"H350, H361, H372"` |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of the reach of children. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | 266.5 °C |
| Lethal dose or concentration | LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | > 130 mg/kg (Rat, oral) |
| NIOSH | CY8 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 200 mg once daily |
| Related compounds | |
| Related compounds |
Arhalofenate Dotinurad Verinurad |
